ASX Announcements.

Date	Price sens.	Headline	pages	PDF
10/01/2020		Immutep Corporate Presentation	33	PDF
09/01/2020	!	Immutep expands Part C of TACTI-002 due to positive data	2	PDF
06/01/2020		Change in substantial holding	6	PDF
02/01/2020		Change of Director's Interest Notice	3	PDF
02/01/2020		Appendix 3B	15	PDF
19/12/2019	!	INSIGHT-004 clinical trial update	3	PDF
09/12/2019		Change of Director's Interest Notice - Mr Meyers	3	PDF
09/12/2019		Change of Director's Interest Notice - Dr Howard	2	PDF
09/12/2019		Change of Director's Interest Notice - Mr Voigt	3	PDF
02/12/2019		Appendix 3B	16	PDF
22/11/2019		Immutep Investor Update	13	PDF
14/11/2019	!	Immutep announces European patent grant for LAG525 antibody	2	PDF
08/11/2019	!	IMM presents positive interim phase 2 TACTI-002 data at SITC	3	PDF
01/11/2019		Update - Consolidation Split - IMM	4	PDF
01/11/2019		2019 AGM CEO Presentation	24	PDF
01/11/2019		2019 AGM Chairman's Address	3	PDF
01/11/2019		Results of Annual General Meeting	2	PDF
31/10/2019		Consolidation/Split - IMM	4	PDF
28/10/2019	!	Operational Update	3	PDF
24/10/2019		Change in substantial holding	6	PDF
23/10/2019	!	Appendix 4C - quarterly	5	PDF
15/10/2019	!	Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma	23	PDF
10/10/2019	!	Immutep receives A$2.5M R&D French Tax Incentive	2	PDF
10/10/2019		Immutep to present data at upcoming Industry Conferences	2	PDF
04/10/2019		Change of Director's Interest Notice - Mr Chamberlain	3	PDF
04/10/2019		Change of Director's Interest Notice - Mr Meyers	3	PDF
03/10/2019		Appendix 3B	15	PDF
30/09/2019		Immutep Investor Presentation	39	PDF
30/09/2019		Notice of Annual General Meeting/Proxy Form	31	PDF
30/09/2019		Annual Report to shareholders	82	PDF
30/09/2019		Appendix 4G & Corporate Governance Statement	32	PDF
26/09/2019	!	Immutep expands Part A of TACTI-002 due to positive data	3	PDF
24/09/2019		Annual Report filed on Form 20-F with SEC	199	PDF
23/09/2019	!	Immutep to receive GBP4M Milestone Payment from GSK	2	PDF
17/09/2019	!	Japanese patent granted for LAG525 antibody	2	PDF
22/08/2019	!	Immutep granted European patent for IMP321 in cancer	2	PDF
20/08/2019	!	Appendix 4E & 2019 Full Year Statutory Accounts	83	PDF
13/08/2019		Ceasing to be a substantial holder from AEF	3	PDF
09/08/2019		Change in substantial holding	5	PDF
07/08/2019		Change of Director's Interest Notice - Mr Chamberlain	2	PDF
07/08/2019		Change of Director's Interest Notice - Mr Voigt	2	PDF
06/08/2019		Immutep completes fully underwritten A$6M Entitlement Offer	2	PDF
01/08/2019	!	Entitlement Offer Results & Shortfall Notification	2	PDF
26/07/2019	!	Operational Update	4	PDF
26/07/2019	!	Appendix 4C - quarterly	5	PDF
19/07/2019		Becoming a substantial holder from AEF	3	PDF
19/07/2019		Change in substantial holding	6	PDF
17/07/2019		Mailing of Offer Booklet for Entitlement Offer	1	PDF
17/07/2019		Cleansing Notice	1	PDF
17/07/2019		Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)	1	PDF
09/07/2019		Cleansing Notice	1	PDF
09/07/2019		Letter to Ineligible Shareholders	2	PDF
09/07/2019		Letter to Eligible Shareholders	3	PDF
09/07/2019		Appendix 3B	14	PDF
09/07/2019	!	Immutep Entitlement Offer Booklet	56	PDF
09/07/2019	!	Immutep Capital Raising Presentation	27	PDF
09/07/2019	!	Immutep raises A$10M via placement & entitlement offer	4	PDF
05/07/2019	!	Trading Halt	2	PDF
25/06/2019	!	Immutep completes recruitment of AIPAC trial in MBC	3	PDF
25/06/2019		Immutep hosts Key Opinion Leader Call	2	PDF
21/06/2019	!	Immutep granted Australian patent for eftilagimod alpha	2	PDF
13/06/2019	!	Immutep completes recruitment of initial NSCLC cohort	2	PDF
06/06/2019	!	First patient dosed in INSIGHT-004	3	PDF
03/06/2019		Appendix 3B	14	PDF
03/06/2019		Immutep Poster Presentation at ASCO	3	PDF
23/05/2019	!	Immutep granted European patent for eftilagimod alpha	2	PDF
17/05/2019	!	More mature positive data for TACTI-mel trial presented	2	PDF
10/05/2019		Immutep to present at upcoming industry conferences	2	PDF
08/05/2019		Becoming a substantial holder	67	PDF
30/04/2019	!	Operational Update	4	PDF
24/04/2019	!	Appendix 4C - quarterly	5	PDF
02/04/2019		Webcast slides for eftilagimod alpha (IMP321)	29	PDF
27/03/2019		Webcast details for update on eftilagimod alpha (IMP321)	2	PDF
26/03/2019		Ceasing to be a substantial holder	10	PDF
25/03/2019		IMP761 Webcast Slides	13	PDF
22/03/2019	!	Immutep granted US patent for IMP321	2	PDF
19/03/2019		Webcast to discuss IMP761 preclinical results	2	PDF
08/03/2019	!	IMP761 results presented at ECCO conference	2	PDF
07/03/2019	!	Immutep receives A$872,351 R&D Tax Incentive	1	PDF
06/03/2019	!	Immutep doses First Patient in TACTI-002 Phase II Trial	4	PDF
06/03/2019	!	TACTI-mel data presented at World Immunotherapy Congress	3	PDF
04/03/2019		Immutep to present at Oppenheimer Healthcare Conference	2	PDF
27/02/2019		Half Year Accounts	29	PDF
26/02/2019		Immutep to present at upcoming industry conferences	2	PDF
25/02/2019		Immutep Presentation to Emergence Conference	18	PDF
31/01/2019		Immutep Investor Update	14	PDF
24/01/2019	!	Appendix 4C - quarterly	5	PDF
07/01/2019	!	Immutep enters into collaboration with CYTLIMIC	3	PDF
04/01/2019		Change of Director's Interest Notice - Dr Howard	3	PDF
04/01/2019		Change of Director's Interest Notice - Mr Voigt	4	PDF
02/01/2019		Appendix 3B	15	PDF
24/12/2018		Becoming a substantial holder	4	PDF
21/12/2018		Disclosure Under LR 3.10.5A and 7.1A.4(b)	2	PDF
21/12/2018		Cleansing Notice	1	PDF
21/12/2018		Appendix 3B	14	PDF
20/12/2018	!	Cleansing prospectus for issue of warrants	46	PDF
19/12/2018	!	Immutep announces US$5.2 million capital raising	3	PDF
29/11/2018	!	European patent granted for IMP321 & antibody combinations	2	PDF
28/11/2018	!	Immutep granted European patent for IMP321	2	PDF
27/11/2018	!	Immutep presents new TACTI-mel data at ICI Europe Summit	3	PDF
26/11/2018		Change of Director's Interest Notice - Dr Howard	2	PDF
21/11/2018		Appendix 3B	14	PDF
16/11/2018		Results of Meeting	3	PDF
16/11/2018		2018 AGM CEO Presentation	23	PDF
16/11/2018		2018 AGM Chairman's Address	3	PDF
12/11/2018	!	Positive interim TACTI-mel data presented at SITC	3	PDF
01/11/2018	!	Operational Update	4	PDF
30/10/2018		AusBiotech Invest presentation slides	11	PDF
25/10/2018	!	Appendix 4C - quarterly	5	PDF
22/10/2018		Annual Report filed on Form 20-F with SEC	127	PDF
11/10/2018		Notice of Annual General Meeting/Proxy Form	27	PDF
11/10/2018		Annual Report to shareholders	80	PDF
11/10/2018		Appendix 4G & Corporate Governance Statement	32	PDF
04/10/2018		Appendix 3B & cleansing notice	15	PDF
02/10/2018		Change of Director's Interest Notice - Mr Chamberlain	3	PDF
02/10/2018		Change of Director's Interest Notice - Mr Meyers	3	PDF
02/10/2018		Appendix 3B & cleansing notice	15	PDF
02/10/2018		Ceasing to be a substantial holder from AEF	3	PDF
02/10/2018		Immutep to present at SITC 2018	2	PDF
28/09/2018		Appendix 3B & cleansing notice	14	PDF
27/09/2018		Appendix 3B & cleansing notice	14	PDF
27/09/2018		Change in substantial holding from AEF	3	PDF
26/09/2018		Immutep to present at Ladenburg Thalmann conference	1	PDF
24/09/2018	!	Immutep enters into collaboration with Pfizer & Merck KGaA	4	PDF
07/09/2018		Immutep presentation for BioCentury NewsMakers conference	29	PDF
03/09/2018		Change in substantial holding from AEF	3	PDF
03/09/2018	!	Progress towards clinical development of IMP761	2	PDF
21/08/2018	!	Appendix 4E & 2018 Full Year Statutory Accounts	82	PDF
21/08/2018	!	Immutep receives A$1.9M from French R&D tax cash rebate	2	PDF
16/08/2018		Immutep to present at BioCentury NewsMakers conference	2	PDF
07/08/2018	!	Immutep secures Canadian patent grant for IMP731 antibody	2	PDF
07/08/2018	!	TACTI-mel Patient Recruitment Complete & Operational Update	3	PDF
31/07/2018	!	Immutep receives IND approval from US FDA for IMP321	2	PDF
30/07/2018	!	Appendix 4C - quarterly	5	PDF
02/07/2018	!	Immutep submits IND application with FDA	2	PDF
19/06/2018		Investor Update	13	PDF
19/06/2018	!	Mid-point of patient enrolment reached in AIPAC trial	2	PDF
04/06/2018		Immutep Poster Presentations at ASCO	2	PDF
30/05/2018	!	Webcast slides for TACTI-mel clinical trial data	25	PDF
30/05/2018	!	New Data from Ongoing TACTI-mel Study	2	PDF
25/05/2018		3rd Annual Advances in Immuno-Oncology Congress Presentation	37	PDF
17/05/2018		Webcast to discuss interim results from TACTI-mel	3	PDF
15/05/2018		Response to ASX Price Query	3	PDF
04/05/2018		Immutep to present at ASCO	2	PDF
23/04/2018		Appendix 4C	5	PDF
13/04/2018		Appendix 3B	13	PDF
13/04/2018		Completion of Share Purchase Plan	2	PDF
03/04/2018	!	Operational Update	2	PDF

SEC Filing.

Date	Filing	Description	Link
2020-01-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-006041 (34 Act) Size: 27 KB	PDF
2020-01-09	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]Acc-no: 0001193125-20-004200 (34 Act) Size: 36 KB	PDF
2020-01-06	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-20-001860 (34 Act) Size: 191 KB	PDF-1, PDF-2
2019-12-20	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-319328 (34 Act) Size: 32 KB	PDF
2019-12-10	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-309656 (34 Act) Size: 77 KB	PDF-1, PDF-2, PDF-3
2019-12-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-305691 (34 Act) Size: 178 KB	PDF
2019-11-15	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-292512 (34 Act) Size: 23 KB	PDF
2019-11-12	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-289148 (34 Act) Size: 40 KB	PDF
2019-11-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-282711 (34 Act) Size: 8 MB	PDF-1, PDF-2. PDF-3. PDF-4
2019-10-29	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-276527 (34 Act) Size: 50 KB	PDF
2019-10-23	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-272123 (34 Act) Size: 107 KB	PDF
2019-10-15	F-3	Registration statement by foreign private issuers Acc-no: 0001193125-19-267683 (33 Act) Size: 359 KB	PDF
2019-10-15	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-267232 (34 Act) Size: 38 KB	PDF
2019-10-09	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-264613 (34 Act) Size: 52 KB	PDF-1, PDF-2
2019-10-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-261937 (34 Act) Size: 171 KB	PDF
2019-10-01	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-259428 (34 Act) Size: 13 MB	PDF-1, PDF-2, PDF-3, PDF-4
2019-09-26	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-255307 (34 Act) Size: 35 KB	PDF
2019-09-24	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-252416 (34 Act) Size: 23 KB	PDF
2019-09-23	20-F	Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Acc-no: 0001193125-19-252176 (34 Act) Size: 13 MB	PDF
2019-09-18	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-247127 (34 Act) Size: 28 KB	PDF
2019-08-22	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-226331 (34 Act) Size: 30 KB	PDF
2019-08-21	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-225441 (34 Act) Size: 1 MB	PDF
2019-08-14	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220211 (34 Act) Size: 10 MB	PDF
2019-08-14	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB	PDF-2
2019-08-14	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-220204 (34 Act) Size: 52 KB	PDF-1
2019-08-07	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-214347 (34 Act) Size: 26 KB	PDF
2019-07-30	D	Notice of Exempt Offering of Securities, item 06b Acc-no: 0001209191-19-043598 (33 Act) Size: 8 KB	PDF
2019-07-30	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-206095 (34 Act) Size: 113 KB	PDF
2019-07-08	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-189823 (34 Act) Size: 68 KB	PDF
2019-06-26	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-181460 (34 Act) Size: 31 KB	PDF
2019-06-21	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-178045 (34 Act) Size: 32 KB	PDF
2019-06-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-171778 (34 Act) Size: 26 KB	PDF
2019-06-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-165320 (34 Act) Size: 27 KB	PDF
2019-06-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-165318 (34 Act) Size: 162 KB	PDF
2019-05-23	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-154569 (34 Act) Size: 22 KB	PDF
2019-05-20	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-150736 (34 Act) Size: 25 KB	PDF
2019-05-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-144945 (34 Act) Size: 36 KB	PDF
2019-05-01	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-130751 (34 Act) Size: 39 KB	PDF
2019-04-26	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-120345 (34 Act) Size: 102 KB	PDF
2019-04-03	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-095885 (34 Act) Size: 11 MB	PDF
2019-03-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-089166 (34 Act) Size: 30 KB	PDF
2019-03-26	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-085849 (34 Act) Size: 4 MB	PDF
2019-03-20	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-079827 (34 Act) Size: 31 KB	PDF
2019-03-11	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-070282 (34 Act) Size: 33 KB	PDF
2019-03-07	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-065913 (34 Act) Size: 45 KB	PDF
2019-03-07	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-065883 (34 Act) Size: 39 KB	PDF
2019-03-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-062670 (34 Act) Size: 46 KB	PDF
2019-02-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-055085 (34 Act) Size: 486 KB	PDF
2019-02-27	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-052155 (34 Act) Size: 27 KB	PDF
2019-02-27	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-050316 (34 Act) Size: 5 MB	PDF
2019-02-14	424B3	Prospectus [Rule 424(b)(3)] Acc-no: 0001193125-19-038345 (33 Act) Size: 337 KB	PDF
2019-02-12	EFFECT	Notice of Effectiveness Acc-no: 9999999995-19-000221 (33 Act) Size: 1 KB	PDF
2019-02-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-027147 (34 Act) Size: 2 MB	PDF
2019-01-14	F-3	Registration statement by foreign private issuers Acc-no: 0001193125-19-008155 (33 Act) Size: 380 KB	PDF
2019-01-08	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-004095 (34 Act) Size: 41 KB	PDF
2019-01-03	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-19-000902 (34 Act) Size: 146 KB	PDF
2018-12-21	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-356488 (34 Act) Size: 305 KB	PDF
2018-12-21	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-356410 (34 Act) Size: 168 KB	PDF-1, PDF-2, PDF-3
2018-12-21	D	Notice of Exempt Offering of Securities, item 06b Acc-no: 0001209191-18-063797 (33 Act) Size: 10 KB	PDF
2018-12-19	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-352838 (34 Act) Size: 27 KB	PDF
2018-12-19	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-352630 (34 Act) Size: 490 KB	PDF-1, PDF-2, PDF-3, PDF-4
2018-12-19	424B5	Prospectus [Rule 424(b)(5)] Acc-no: 0001193125-18-352623 (33 Act) Size: 488 KB	PDF
2018-11-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-335585 (34 Act) Size: 32 KB	PDF
2018-11-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-335435 (34 Act) Size: 36 KB	PDF
2018-11-27	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-334115 (34 Act) Size: 27 KB	PDF
2018-11-23	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-332532 (34 Act) Size: 193 KB	PDF
2018-11-19	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329689 (34 Act) Size: 39 KB	PDF
2018-11-19	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB	PDF-2
2018-11-19	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-329687 (34 Act) Size: 8 MB	PDF-1
2018-11-16	CT ORDER	Confidential treatment order Acc-no: 9999999997-18-009006 (34 Act) Size: 105 KB	PDF
2018-11-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-324662 (34 Act) Size: 38 KB	PDF
2018-11-07	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-319727 (34 Act) Size: 33 KB	PDF
2018-10-31	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-312572 (34 Act) Size: 4 MB	PDF
2018-10-26	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-308011 (34 Act) Size: 102 KB	PDF
2018-10-25	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-306696 (34 Act) Size: 34 KB	PDF
2018-10-19	20-F	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-302492 (34 Act) Size: 581 KB	PDF
2018-10-17	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300562 (34 Act) Size: 888 KB	PDF
2018-10-17	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300478 (34 Act) Size: 15 MB	PDF
2018-10-17	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-300442 (34 Act) Size: 247 KB	PDF
2018-10-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-293981 (34 Act) Size: 127 KB	PDF
2018-10-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-292668 (34 Act) Size: 184 KB	PDF-1, PDF-2, PDF-3
2018-10-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-292527 (34 Act) Size: 119 KB	PDF
2018-10-03	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-291188 (34 Act) Size: 23 KB	PDF
2018-10-01	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-288121 (34 Act) Size: 118 KB	PDF
2018-09-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB	PDF-2
2018-09-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285992 (34 Act) Size: 114 KB	PDF-1
2018-09-28	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-285955 (34 Act) Size: 28 KB	PDF
2018-09-10	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-269333 (34 Act) Size: 2 MB	PDF
2018-09-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-266455 (34 Act) Size: 34 KB	PDF
2018-08-24	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB	PDF-2
2018-08-24	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-256678 (34 Act) Size: 1 MB	PDF-1
2018-08-17	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-251021 (34 Act) Size: 21 KB	PDF
2018-08-08	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB	PDF-2
2018-08-08	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-241616 (34 Act) Size: 56 KB	PDF-1
2018-08-01	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-233634 (34 Act) Size: 24 KB	PDF
2018-07-31	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-232248 (34 Act) Size: 108 KB	PDF
2018-07-03	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-211709 (34 Act) Size: 35 KB	PDF
2018-06-20	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-197123 (34 Act) Size: 3 MB	PDF-1 PDF-2
2018-06-05	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-183678 (34 Act) Size: 34 KB	PDF
2018-05-31	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-179361 (34 Act) Size: 10 MB	PDF-1 PDF-2
2018-05-30	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-177481 (34 Act) Size: 9 MB	PDF
2018-05-18	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-166845 (34 Act) Size: 33 KB	PDF
2018-05-07	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-153820 (34 Act) Size: 32 KB	PDF
2018-04-23	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-131968 (34 Act) Size: 117 KB	PDF
2018-04-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-117066 (34 Act) Size: 21 KB	PDF
2018-04-13	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-117059 (34 Act) Size: 115 KB	PDF
2018-04-04	6-K	Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-18-106513 (34 Act) Size: 29 KB	PDF

ASX Announcements.

SEC Filing.

Financial Information.